Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1993-05-03
2000-07-04
Sayala, Chhaya D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530356, A61K 3817, A61K 3839
Patent
active
06083918&
DESCRIPTION:
BRIEF SUMMARY
The invention relates to the use of collagen for the treatment of degenerative articular processes.
The basic type of degenerative, non-inflammatory joint diseases is arthropathy or Arthrosis deformans in old age. Squat-bodied human beings, more men than women, after the 50th year are mainly affected. The condition begins slowly, but also progresses intermittently and at the beginning without pain. The joints are only tender upon certain movements. Avoiding strain on the joints promotes the progression of the condition, but exercise and massages afford relief. Good successes can also be achieved by the treatment with ultra-short waves.
Further therapies, which have been customary so far, are the systematic administration of non-steroidal antirheumatic agents and possibly intra-articular injections of agents for the protection of cartilage, homoeopathic agents, local anaesthetics or cortisone. However, these therapies have the disadvantage that the destruction of the joints occurring finally due to degenerative joint processes cannot be prevented, but only delayed, since the new formation of synovial fluids, such as mucopolysaccharides, cannot be stimulated, and no synovial fluid is introduced into the affected joint from the outside.
Reconstituted type II collagen can be used for the detection of antibodies against intact type II collagen in the blood in the case of arthrorheumatism (JP-A 62-012 800).
Collagens are long-fibred, linear-colloid, highly molecular scleroproteins of the extracellular matrix, which are found in connective tissues (e.g. skin, cartilage, sinews, ligaments and blood vessels), in the protein-containing ground substance of the bone (ossein) and in dentin together with proteoglycans. With a share of 25 to 30% they are considered to be the quantitatively most frequent animal proteins. The structural basic unit of collagen, the tropocollagen (MW approx. 300,000), consists of three polypeptide chains in the form of special left-wound helices which, in turn, are righthandedly twisted around one other according to the technique known in ropery (triple helix). The tropocollagen molecule is a "rope" with a length of 280 nm and a diameter of 1.4 nm; the fibrils have a cross-section of 200 to 500 nm (see Rompps Chemielexikon, vol. 3, page 2297, 1990).
As opposed to most proteins of the animal body, the collagens are not continuously renewed. Once they are formed, they do not participate in the metabolism any more and age due to regular increase in cross-linking due to the formation of hydrogen bridge bonds, ester bonds of amino acid residues with sugar residues and of isopeptide bonds between long-chain amino acid chains.
Modified collagen is used in medicine as a temporary skin replacement, as a replacement for cornea and vitreous humour of the eye, as a replacement for sinews, synovial sheaths, hollow organs and blood vessels, as a blood plasma substitute and in wound healing (EP-B 52288, JP-A-52-076 416). Collagen sponge is intraarticularily used as a haematostatic. Collagen containing drugs are used to improve dilatable deformations of the skin as they occur in scars, in skin atrophy caused by various causes and in skin creases caused by age. These collagen-containing drugs are injected under the skin areas to be filled and, for this reason, contain, as a rule, a local anaesthetic.
It is the object of the present invention to produce a drug for the therapy of degenerative articular processes which does not have the aforementioned disadvantages.
This object is attained according to the invention by using collagen for producing a drug for the treatment of degenerative articular processes.
The used collagen is unsoluble collagen, which can e.g. be obtained from calf and bovine skin; however, collagen from bovine skin is preferred.
The collagen is preferably contained in an injection suspension, particularly preferred in an amount of about 20 to 50 mg/ml. The injection suspension is applied by means of injection into the joints according to the invention in the case of degenerative articular d
REFERENCES:
patent: 3683076 (1972-08-01), Rovati
patent: 3966908 (1976-06-01), Balassa
patent: 4473551 (1984-09-01), Schinitsky
patent: 4582640 (1986-04-01), Smestad et al.
patent: 4704273 (1987-11-01), McMichael
patent: 4804745 (1989-02-01), Koepff et al.
patent: 5002071 (1991-03-01), Harrel
patent: 5036056 (1991-07-01), Kludas
patent: 5137875 (1992-08-01), Tsunenaga et al.
patent: 5639796 (1997-06-01), Lee
Myers, L. K et al, "A CD4 Cell is Capable of Transferring Suppression . . . ", J. Immunol., 143 (12), 1989, pp. 3976-3980.
Stedman's Medical Dictionary, 24.sup.th Edn, p. 271, 1982.
Moya, NIDA Res. Monoar. Ser., vol. 36, pp. 118-121, 1981.
Carron, Geriatrics, vol. 33(4), pp. 49-57, 1978.
LandOfFree
Use of collagen for the treatment of degenerative articular proc does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of collagen for the treatment of degenerative articular proc, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of collagen for the treatment of degenerative articular proc will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1486645